文献速递心律失常血脂与心血管预防

90岁及以上房颤患者的口服抗凝治疗:全国队列研究

Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study.
PubMed 文献 · Circulation · 2018-02-28

基于台湾全民健康保险研究数据库,1996-2011年比较≥90岁房颤与非房颤患者缺血性卒中和颅内出血风险,并分析华法林与抗血小板药及未治疗的风险差异;2012-2015年进一步比较华法林与NOACs。结果显示房颤增加缺血性卒中风险,华法林降低卒中风险且净临床获益为正,NOACs较华法林降低颅内出血风险。

要点

  • ≥90岁房颤患者缺血性卒中风险显著高于非房颤者,颅内出血风险相似。
  • 华法林较未治疗降低缺血性卒中风险,且不增加颅内出血,净临床获益为正。
  • 与华法林相比,NOACs降低颅内出血风险,缺血性卒中风险无差异。

核心结论

  • 在≥90岁房颤患者中,华法林与较低的缺血性卒中风险和正的净临床获益相关。
  • 与华法林相比,NOACs与较低的颅内出血风险相关。
  • 口服抗凝药仍可考虑用于高龄患者血栓预防,NOACs是更有利的选择。

研究设计与样本

  • 使用台湾全民健康保险研究数据库的全国性队列研究。
  • 2012-2015年NOACs可用期间,进一步比较华法林与NOACs治疗的卒中和颅内出血风险。

主要发现

  • 与未治疗或抗血小板药相比,华法林净临床获益为正,倾向性匹配分析结果一致。
  • 与华法林相比,NOACs组颅内出血发生率为0.42%/年(4/978),华法林组为1.63%/年(19/768),风险比0.32(95%CI 0.10-0.97),缺血性卒中风险无差异。

临床怎么用

  • ≥90岁房颤患者仍可考虑口服抗凝药进行血栓预防。
  • 华法林可降低缺血性卒中风险且净临床获益为正。
  • NOACs较华法林颅内出血风险更低,可能是更有利的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke prevention with oral anticoagulants (OACs) is the cornerstone for the management of atrial fibrillation (AF). However, data about the use of OACs among patients ≥90 years of age are limited. We aimed to investigate the risk of ischemic stroke and intracranial hemorrhage (ICH) and the net clinical benefit of OAC treatment for very elderly patients with AF (≥90 years of age). METHODS: This study used the National Health Insurance Research Database in Taiwan. Risks of ischemic stroke and ICH were compared between 11 064 and 14 658 patients with and without AF ≥90 years of age without antithrombotic therapy from 1996 to 2011. Patients with AF (n=15 756) were divided into 3 groups (no treatment, antiplatelet agents, and warfarin), and the risks of stroke and ICH were analyzed. The risks of ischemic stroke and ICH were further compared between patients treated with warfarin and nonvitamin K antagonist OACs (NOACs) from 2012 to 2015 when NOACs were available in Taiwan. RESULTS: Compared with patients without AF, patients with AF had an increased risk of ischemic stroke (event number/patient number, incidence = 742/11 064, 5.75%/y versus 1399/14 658, 3.00%/y; hazard ratio, 1.93; 95% confidence interval, 1.74-2.14) and similar risk of ICH (131/11 064, 0.97%/y versus 206/14 658, 0.54%/y; hazard ratio, 0.85; 95% confidence interval, 0.66-1.09) in competing risk analysis for mortality. Among patients with AF, warfarin use was associated with a lower stroke risk (39/617, 3.83%/y versus 742/11 064, 5.75%/y; hazard ratio, 0.69; 95% confidence interval, 0.49-0.96 in a competing risk model), with no difference in ICH risk compared with nontreatment. When compared with no antithrombotic therapy or antiplatelet drugs, warfarin was associated with a positive net clinical benefit. These findings persisted in propensity-matched analyses. Compared with warfarin, NOACs were associated with a lower risk of ICH (4/978, 0.42%/y versus 19/768, 1.63%/y; hazard ratio, 0.32; 95% confidence interval, 0.10-0.97 in a competing risk model), with no difference in risk of ischemic stroke. CONCLUSIONS: Among patients with AF ≥90 years of age, warfarin was associated with a lower risk of ischemic stroke and positive net clinical benefit. Compared with warfarin, NOACs were associated with a lower risk of ICH. Thus, OACs may still be considered as thromboprophylaxis for elderly patients, with NOACs being the more favorable choice.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chao TF, Liu CJ, Lin YJ, et al. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation. 2018. PMID: 29490992. doi:10.1161/CIRCULATIONAHA.117.031658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。